How effective is zoledronic acid?

Zoledronic acid belongs to the bisphosphonate class of drugs. Its main function is to inhibit the destruction of bone cells. It is also used for bone metastasis cancer and has a bone-protecting effect. On the one hand, its effect can protect bone cells and have a certain analgesic effect. In combination with standard antineoplastic drug therapy, it is indicated for the treatment of skeletal lesions in patients with solid tumor bone metastases and multiple myeloma. For the treatment of hypercalcemia (HCM) caused by malignancy.

How effective is zoledronic acid?

Postmenopausal osteoporosis (PM0P) patients who met the inclusion criteria and were admitted to the clinical trial from January 2013 to January 2014 were used as the research subjects. A total of 210 PMOP patients were enrolled, and the patients were randomly divided into the zoledronic acid group (105 cases) and the alendronate sodium group (105 cases). Patients in the zoledronic acid group received intravenous infusion of 5 mg of zoledronic acid injection once a year, and patients in the alendronate sodium group took 70 mg of alendronate sodium once a week. The treatment course for both groups was 24 months.

After treatment, the bone mineral density of the lumbar spine and hip in the zoledronic acid group and the alendronate group were (-1.56±0.35) g/cm2 and (-2.21±0.54) g/cm2, (-1.91±0.32) g/cm2 and (-2.16±0.26) g/cm2 respectively, which were significantly increased compared with before treatment. However, the increase in bone density of the lumbar spine and hip in the zoledronic acid group was significantly higher than that in the alendronate group. The VAS scores of the alendronate group and the zoledronic acid group at 12 and 24 months after treatment were (4.02±0.50) points and (3.01±0.44) points, (2.95±0.36) points and (1.82±0.24) points respectively, which were significantly lower than before treatment. The VAS scores of the treatment group at 12 and 24 months after treatment were significantly lower than those of the alendronate group. The incidence of fever in the alendronate group was 2.86% (3/105), which was lower than 30.48% (32/105) in the zoledronic acid group. Both zoledronic acid injection and alendronate sodium can effectively treat PMOP, but zoledronic acid is more effective in increasing bone density, reducing bone pain, and has better compliance. Although it increases the incidence of adverse reactions, it is well tolerated.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: